MBrace Therapeutics capitalizes on ADC wave with $85M Series B to enter the clinic this quarter
MBrace Therapeutics has raised an $85 million Series B for a Phase I clinical trial of its first antibody-drug conjugate as investors and Big Pharmas pump billions of dollars into ADCs, a type of cancer treatment that has ballooned from a niche of oncology R&D to a centerpiece of industry dealmaking.
The San Diego-based biotech, which is born out of research from a Rutgers University wife-and-husband duo, has two ADCs in the works, CEO Isan Chen told Endpoints News. The startup is going after new targets with ADCs rather than trying to be a fast follower or a me-too type of company trying to make the next TROP2-, Nectin4- or HER2-targeted cancer treatment, the CEO added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.